Results 201 to 210 of about 16,238 (237)

TNF Receptor-Associated Periodic Syndrome: An Analysis of a Slovakian Cohort of TRAPS Patients. [PDF]

Arch Rheumatol
Slenker B, Banovcin P, Hrubiskova K, Vargova V, Bobcakova A, Gensor D, Malicherova Jurkova E, Kapustova D, Kapustova L, Markocsy A, Petrovicova O, Jesenak M.   +11 more
europepmc   +1 more source

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. [PDF]

Cancer Res Commun
Solomon BJ, Tan DSW, de Castro G, Cobo M, Garassino MC, Zhang J, Johnson BE, Lee JM, Garrido P, Butler AA, Pelletier MR, Savchenko A, Ji L, Brase JC, Caparica R, Demanse D, Wu J, Bossen C, Mok T.   +18 more
europepmc   +1 more source

Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study. [PDF]

BMJ Open
Hepprich M, Fischer J, Cattaneo M, Ferreira A, Herzig D, Bally L, Donath M.   +6 more
europepmc   +1 more source

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [PDF]

New England Journal of Medicine, 2017
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.
Paul M Ridker, Tom Thuren, Francisco Fonseca   +2 more
exaly   +9 more sources

Some of the next articles are maybe not open access.

Related searches:

Canakinumab

Reactions Weekly, 2019
  +10 more sources

Canakinumab

Reactions Weekly, 2022
  +5 more sources